Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Quarterly results
CC transcript
Appointed director
Covidien plc (COV) Create: Alert

All | News | Filings
Date FiledTypeDescription
01/22/2015 8-K Quarterly results
Docs: "Covidien Reports First-Quarter 2015 Results • First-quarter net sales up 2% • First-quarter diluted GAAP earnings per share were $1.12; excluding specified items, adjusted diluted earnings per share were $1.11"
11/05/2014 8-K Quarterly results
Docs: "Covidien Reports Fourth-Quarter and Fiscal 2014 Results • Fourth-quarter net sales up 7%; Medical Devices sales up 8% • Fourth-quarter diluted GAAP earnings per share were $1.13; excluding specified items, adjusted diluted earnings per share were $1.15 • Fiscal 2014 diluted GAAP earnings per share were $3.65; excluding specified items, adjusted diluted earnings per share were $4.15, up 12%"
07/25/2014 8-K Quarterly results
Docs: "Covidien Reports Third-Quarter Fiscal 2014 Results • Net sales up 4%; Medical Devices sales up 5% • Third-quarter diluted GAAP earnings per share were $0.67; excluding specified items, adjusted diluted earnings per share were $1.04, up 14%"
04/25/2014 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter Fiscal 2014 Results • Net sales up 3% • Second-quarter diluted GAAP earnings per share were $0.97; excluding specified items, adjusted diluted earnings per share were $0.96"
01/24/2014 8-K Quarterly results
Docs: "Covidien Reports First-Quarter Fiscal 2014 Results • Net sales up 3% ; Medical Devices sales up 3% • First-quarter diluted GAAP earnings per share were $0.87; excluding specified items, adjusted diluted earnings per share were $1.00"
11/08/2013 8-K Form 8-K - Current report
08/01/2013 8-K Quarterly results
Docs: "Covidien Reports Third-Quarter Results • Net sales up 3% ; Medical Devices sales up 4% • Third-quarter diluted GAAP earnings per share from continuing operations were $0.85; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.91"
04/26/2013 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter Results • Net sales up 5% ; Medical Devices sales up 4% • Second-quarter diluted GAAP earnings per share from continuing operations were $0.93; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.12"
01/25/2013 8-K Quarterly results
Docs: "Covidien Reports First-Quarter Results • Net sales up 5%; Medical Devices sales up 8% • First-quarter diluted GAAP earnings per share were $1.03; excluding specified items, adjusted diluted earnings per share were $1.10 • Increasing fiscal 2013 net sales guidance in all segments"
11/09/2012 8-K Quarterly results
Docs: "Covidien Reports Fourth-Quarter and Fiscal 2012 Results"
07/26/2012 8-K Form 8-K - Current report
04/27/2012 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter Results • Net sales up 5%; Medical Devices sales up 7% • Second-quarter diluted GAAP earnings per share from continuing operations were $1.01; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.05, up 13%"
01/26/2012 8-K Quarterly results
Docs: "Covidien Reports First-Quarter Results • Net sales up 5%; Medical Devices sales up 6% • First-quarter diluted GAAP earnings per share from continuing operations were $1.02; excluding specified items, adjusted diluted earnings per share from continuing operations were $1.13, up 19% • Fiscal 2012 sales guidance updated"
11/15/2011 8-K Form 8-K - Current report
04/21/2011 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter Results • Net sales up 10%; Medical Devices sales up 16% • Second-quarter diluted GAAP earnings per share from continuing operations were $0.92; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.93, up 8% • Fiscal 2011 guidance updated"
02/01/2011 8-K Form 8-K - Current report
11/09/2010 8-K Form 8-K - Current report
07/29/2010 8-K Form 8-K - Current report
04/21/2010 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter 2010 Results"
01/20/2010 8-K Quarterly results
Docs: "Covidien Reports First-Quarter 2010 Results",
"Financial Information"
11/17/2009 8-K Form 8-K - Current report
04/30/2009 8-K Form 8-K -- Current report
01/26/2009 8-K Quarterly results
Docs: "Covidien Reports First-Quarter 2009 Results"
11/17/2008 8-K Quarterly results
Docs: "Covidien Reports Fourth-Quarter and Fiscal 2008 Results"
08/05/2008 8-K Quarterly results
Docs: "Covidien Reports Third-Quarter 2008 Results"
05/06/2008 8-K Quarterly results
Docs: "Covidien Reports Second-Quarter 2008 Results"
02/07/2008 8-K Quarterly results
Docs: "Covidien Reports First-Quarter 2008 Results",
"Revised Fiscal 2007 Financial Information"
12/06/2007 8-K Quarterly results
Docs: "Covidien Ltd. Consolidated and Combined Statements of Operations Quarters Ended September 28, 2007 and September 29, 2006 Quarters Ended September 28, 2007 Percent of Net Sales September 29, 2006 Percent of Net Sales Net sales $ 2,601 100.0 % $ 2,481 100.0 % Cost of products sold 1,354 52.1 % 1,341 54.1 % Gross profit 1,247 47.9 % 1,140 45.9 % Selling, general and administrative expenses 697 26.8 % 520 21.0 % Research and development expenses 77 3.0 % 68 2.7 % In-process research and development charges — 0.0 % 60 2.4 % Class action settlement, net of insurance recoveries -0.2 % — 0.0 % Impairments of long-lived assets 290 11.1 % — 0.0 % Restructuring and other charges, net 32 1.2 % — 0.0 % on divestiture — 0.0 % -0.1 % Operating income 156 6.0 % 495 20.0 % Interest expense 63 2.4 % 40 1.6..."
08/09/2007 8-K Quarterly results
Docs: "Covidien Ltd. Combined Statements of Operations Quarters Ended June 29, 2007 and June 30, 2006 Quarters Ended June 29, 2007 Percent of Net Sales June 30, 2006 Percent of Net Sales Net sales $ 2,579 100.0 % $ 2,464 100.0 % Cost of products sold 1,337 51.8 1,306 53.0 Gross profit 1,242 48.2 1,158 47.0 Selling, general and administrative expenses 662 25.7 536 21.8 Research and development expenses 68 2.6 64 2.6 Class action settlement, net of insurance recovery 1,207 46.8 — — Restructuring charges 5 0.2 — — Loss on divestiture — — 1 — In-process research and development charge 30 1.2 — — Operating income 557 22.6 Interest expense 46 1.8 40 1.6 Interest income Other expense, net 156 6.0 1 — income from continuing operations before income taxes 522 21.2 Income taxes 184 7.1 135 5.5 income f..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy